Obsidian Therapeutics

Obsidian Therapeutics is a clinical-stage biotechnology company that develops engineered cell and gene therapies to provide transformative outcomes for patients with intractable diseases. Their proprietary cytoDRiVE® technology allows for precise regulation of protein function using FDA-approved small molecules. The company is headquartered in Cambridge, MA, and has ongoing collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals.

Obsidian’s lead product candidate is OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) cell therapy armed with regulated membrane-bound IL15. OBX-115 is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TIL therapies, which could potentially lead to improved clinical outcomes for patients suffering from different types of solid tumors. The company is actively enrolling patients in two ongoing clinical trials of OBX-115 in advanced melanoma and non-small cell lung cancer.

Obsidian Therapeutics offers flexible time off, six weeks of fully paid bonding leave for new parents, and a generous annual Health Savings Account contribution. These policies reflect their commitment to supporting employee well-being and allowing individuals to balance their work and personal lives.

Obsidian Therapeutics offers a comprehensive benefits package for employees that includes competitive salaries, comprehensive health, dental, and vision insurance with low out-of-pocket costs, generous paid time off, six weeks of fully paid bonding leave for parents, and a flexible time off program. They also offer employee stock options, a 401K, and health savings accounts for long-term value, as well as benefits that promote employee well-being, such as gym memberships, massage therapy, and meditation reimbursements. They also provide career growth opportunities, including mentorship, training programs, and tuition reimbursement, and are committed to gender pay equity.

Obsidian Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of engineered cell and gene therapies. They leverage their proprietary cytoDRiVE® platform to create precision medicines that address intractable diseases. The company aims to deliver transformative outcomes for patients by harnessing the power of regulated therapeutic proteins, resulting in enhanced persistence, antitumor activity, and clinical safety of their engineered cell therapies.

Obsidian Therapeutics fosters a collaborative and innovative culture where curiosity and urgency are highly valued. The company emphasizes teamwork and open communication, encouraging employees to share ideas and learn from each other. They believe in authenticity, valuing diversity of thought and experience, and creating an environment where individuals can be their whole selves.

Obsidian Therapeutics values the diversity of its team, seeing it as a source of strength. They believe that varied backgrounds, identities, and experiences contribute to their collective knowledge, intellect, and energy. This commitment to diversity is reflected in their company culture, which emphasizes collaboration, authenticity, and a welcoming environment for all.